Les facteurs de croissance (CSF) biosimilaires: une avancée ?

Biosimilar drugs are coming on to the supportive care market, especially factors acting on the granulocyte series and stimulators of erythropoeisis. Their availability is provoking a great deal of thought and discussion. Are they truly drugs, why are they cheaper, are they safe, do they represent real progress or are they just simple copies? The elaboration of a biosimilar medication is a response to scientific and regulatory demands, which pose a real challenge in terms of fundamental research. This is reflected in the basic process of preclinical and then clinical development. Savings that can be made during this development facilitate a reduction in the price of the product and provide essential reductions in health costs.